Targeting pandemic influenza : a primer on influenza antivirals and drug resistance

The emergence of the 2009 H1N1 pandemic influenza A virus, as well as constant antigenic drift of seasonal influenza, underscores the remarkable versatility of this virus in adapting to the human population. While vaccines are the principal public health defence against influenza, rapid vaccine development can be a daunting task. Antiviral drugs offer the promise of inhibiting influenza regardless of its genetic variations. However, the rapid rise of resistance to several antivirals has highlighted the need for developing novel therapeutics with reduced drug resistance potential. In this review, we will summarize the effects of the currently licensed anti-influenza drugs as well as the candidates in development against the seasonal and the 2009 H1N1 pandemic influenza A virus with an emphasis on drug resistance.

Medienart:

E-Artikel

Erscheinungsjahr:

2010

Erschienen:

2010

Enthalten in:

Zur Gesamtaufnahme - volume:65

Enthalten in:

The Journal of antimicrobial chemotherapy - 65(2010), 6 vom: 11. Juni, Seite 1086-93

Sprache:

Englisch

Beteiligte Personen:

Moss, Ronald B [VerfasserIn]
Davey, Richard T [VerfasserIn]
Steigbigel, Roy T [VerfasserIn]
Fang, Fang [VerfasserIn]

Links:

Volltext

Themen:

20O93L6F9H
227R1C272Q
Acids, Carbocyclic
Antiviral Agents
Cyclopentanes
Guanidines
Journal Article
L6O3XI777I
Oplunofusp
Oseltamivir
Peramivir
QW7Y7ZR15U
Recombinant Fusion Proteins
Review
Zanamivir

Anmerkungen:

Date Completed 09.08.2010

Date Revised 09.12.2020

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1093/jac/dkq100

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM19718751X